Immune cell infiltration is associated with the prognosis of cancer. This study focused on the immune infiltration profiling and their association with survival outcome in nonsmall cell lung cancer (NSCLC). Research data were obtained from the Gene Expression Omnibus and The Cancer Genome Atlas databases. CIBERSORT algorithm was applied to assess the relative proportions of 22 kinds of immune cells. Log-rank test was performed to compare the survival outcome of patients with different proportions of immune cells. The estimated hazard ratios were presented with forest plot. Multivariate Cox regression analysis was conducted to estimate the adjusted associations between different types of infiltrating immune cells and survival prognosis controlling for other clinical features and confounders. With the CIBERSORT approach, we assessed the proportions of 22 infiltrating immune cells of 2050 cases with NSCLC. By conducting survival analysis, we found different survival outcomes among cases with different proportions of certain types of infiltrating immune cells. Among the cell subsets investigated, plasma cells (hazard ratio [HR] = 0.775, 95% confidence interval [CI]: 0.669–0.898) and regulatory T cells (HR = 1.258, 95% CI: 1.091–1.451) were associated with survival outcome of NSCLC patients controlling for other covariates. Subgroup analysis suggested a good consistency and robustness of our results. Our findings might provide useful information for prognosis prediction and cellular study in NSCLC.
Get full access to this article
View all access options for this article.
References
1.
AbediS., JanbabaeiG., AfshariM., MoosazadehM., Rashidi AlashtiM., Hedayatizadeh-OmranA., et al. (2019). Estimating the survival of patients with lung cancer: what is the best statistical model?. J Prev Med Public Health, 52, 140–144.
2.
AliH., ChlonL., PharoahP., MarkowetzF., and CaldasC. (2016). Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med 13,e1002194.
3.
AnsellS.M., LesokhinA.M., BorrelloI., HalwaniA., ScottE.C., GutierrezM., et al. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372, 311–319.
4.
BarbiJ., PardollD., and PanF. (2014). Treg functional stability and its responsiveness to the microenvironment. Immunol Rev, 259, 115–139.
5.
BaxevanisC., PapamichailM., and PerezS. (2013). Immune classification of colorectal cancer patients: impressive but how complete?. Expert Opin Biol Ther, 13, 517–526.
6.
BenjaminiY., and HochbergY. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple hypothesis testing. J R Stat Soc B, 57, 289–300.
7.
BildA.H., YaoG., ChangJ.T., WangQ., PottiA., ChasseD., et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 19, 353–357.
8.
BrahmerJ.R., TykodiS.S., ChowL.Q., HwuW.J., TopalianS.L., HwuP., et al. (2012). Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N Engl J Med, 366, 2455–2465.
9.
BremnesR.M., BusundL.T., KilvaerT.L., AndersenS., RichardsenE., PaulsenE.E., et al. (2016). The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol, 11, 789–800.
10.
BotlingJ., EdlundK., LohrM., HellwigB., HolmbergL., LambeM., et al. (2013). Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res, 19, 194–204.
11.
ChenZ., Gerhold-AyA., GebhardS., BoehmD., SolbachC., LebrechtA., et al. (2012). Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 7,e44741.
12.
CollinsL.G., HainesC., PerkelR., and EnckR.E. (2007). Lung cancer: diagnosis and management. Am Fam Physician, 75, 56–63.
13.
CurielT., CoukosG., ZouL., AlvarezX., ChengP., MottramP., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, 942–949.
14.
DerS.D., SykesJ., PintilieM., ZhuC.Q., StrumpfD., LiuN., et al. (2014). Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol, 9, 59–64.
15.
DimitrakopoulosF., KottorouA., AntonacopoulouA., PanagopoulosN., ScopaC., KalofonouM., et al. (2019). Expression of immune system-related membrane receptors CD40, RANK, BAFFR and LTβR is associated with clinical outcome of operated non-small-cell lung cancer patients. J Clin Med 8,741.
16.
DjenidiF., AdamJ., GoubarA., DurgeauA., MeuriceG., de MontprévilleV., et al. (2015). CD8+CD103+ tumor–infiltrating lymphocytes are tumor-specific tissue-resident memory t cells and a prognostic factor for survival in lung cancer patients. J Immunol, 194, 3475–3486.
17.
Doria-RoseV.P., MarcusP.M., MillerA.B., BergstralhE.J., MandelJ.S., TockmanM.S., et al. (2010). Does the source of death information affect cancer screening efficacy results?. A study of the use of mortality review versus death certificates in four randomized trials. Clin Trials, 1, 69–77.
18.
DyckL., and MillsK. (2017). Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol, 47, 765–779.
19.
ElinavE., NowarskiR., ThaissC., HuB., JinC., and FlavellR.A. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer, 13, 759–771.
20.
GajewskiT., MengY., BlankC., BrownI., KachaA., KlineJ., et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunol Rev, 213, 131–145.
21.
GentlesA.J., NewmanA.M., LiuC.L., BratmanS.V., FengW., KimD., et al. (2015). The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med, 21, 938–945.
22.
GnjaticS., BronteV., BrunetL.R., ButlerM.O., DisisM.L., GalonJ., et al. (2017). Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer, 5. DOI:10.1186/s40425-017-0243-4.
23.
HiraokaK., MiyamotoM., ChoY., SuzuokiM., OshikiriT., NakakuboY., et al. (2006). Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favorable prognostic factor in non-small-cell lung carcinoma. Br J Cancer, 94, 275–280.
24.
IkedaS., FunakoshiN., InagakiM., and ShibataT. (2006). Clinicopathologic roles of tumor-infiltrating lymphocytes and CD8-positive lymphocytes in lung cancer imprint smears in squamous cell carcinoma and adenocarcinomas. Acta Cytol, 50, 423–429.
25.
KroegerD., MilneK., and NelsonB. (2016). Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic t-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res, 22, 3005–3015.
26.
LiuX., WuS., YangY., ZhaoM., ZhuG., and HouZ. (2017). The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother, 95, 55–61.
27.
LokodyI. (2014). Microenvironment: tumor-promoting tissue mechanics. Nat Rev Cancer 14,296.
28.
MazzaschiG., MadedduD., FalcoA., BocchialiniG., GoldoniM., SogniF., et al. (2018). Low PD-1 expression in cytotoxic CD8+ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res. 24, 407–419.
29.
MelicharB., SavaryC., PateniaR., TemplinS., MelicharovaK., and FreedmanR.S. (2010). Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer, 13, 435–443.
30.
McCarthyN. (2014). Tumor microenvironment: more than just a mutagen. Nat Rev Cancer 14,213.
31.
MitchellK.A., ZingoneA., ToulabiL., BoeckelmanJ., and RyanB.M. (2017). Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans. Clin Cancer Res, 23, 7412–7425.
32.
MlecnikB., BindeaG., AngellH., MabyP., AngelovaM., TougeronD., et al. (2016). Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival tan microsatellite instability. Immunity, 44, 698–711.
33.
MoonE., LangerC., and AlbeldaS. (2017). The era of checkpoint blockade in lung cancer: taking the brakes off the immune system. Ann Am Thorac Soc, 14, 1248–1260.
34.
MoriM., OhtaniH., NaitoY., SagawaM., SatoM., FujimuraS., et al. (2000). Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med, 191, 113–118.
35.
NairS., BoczkowskiD., FassnachtM., PisetskyD., and GilboaE. (2007). Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res, 67, 371–380.
36.
NandaR., ChowL.Q., DeesE.C., BergerR., GuptaS., GevaR., et al. (2016). Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol, 34, 2460–2467.
37.
NewmanA.M., LiuC., GreenM.R., GentlesA.J., FengW., XuY., et al. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 12, 453–457.
38.
NielsenJ.S., SahotaR.A., MilneK., KostS.E., NesslingerN.J., WatsonP.H., et al. (2012). CD20þ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8þ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18, 3281–3292.
39.
Nitcheu-TefitJ., DaiM., Critchley-ThorneR., Ramirez-JimenezF., XuM., ConchonS., et al. (2007). Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J Immunol, 179, 1532–1541.
40.
PetersenR.P., CampaM.M., SperlazzaJ., ConlonD., JoshiM.B., HarpoleD.H.Jr, et al. (2006). Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, 107, 2866–2872.
41.
PiconeseS., ValzasinaB., and ColomboM. (2008). OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205,1505.
42.
PowellD. Jr., Felipe-SilvaA., MerinoM., AhmadzadehM., AllenT., LevyC., et al. (2007). Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol, 179, 4919–4928.
43.
RacleJ., de JongeK., BaumgaertnerP., SpeiserD.E., and GfellerD. (2017). Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife, 6. DOI:10.7554/eLife.26476
44.
RaponiM., ZhangY., YuJ., ChenG., LeeG., TaylorJ.M., et al. (2006). Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res, 66, 7466–7472.
45.
Rohr-UdilovaN., KlinglmüllerF., Schulte-HermannR, StiftJ., HeracM., SalzmannM., et al. (2018). Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep 8,6220.
46.
RuffiniE., AsioliS., FilossoP.L., LyberisP., BrunaM.C., MacrìL., et al. (2009). Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg, 87, 365–372.
47.
SiegelR.L., MillerK.D., and JemalA. (2019). Cancer statistics, 2019. CA Cancer J Clin, 69, 7–34.
48.
TangH., XiaoG., BehrensC., SchillerJ., AllenJ., ChowC.W., et al. (2013). A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res, 19, 1577–1586.
49.
TomidaS., KoshikawaK., YatabeY., HaranoT., OguraN., MitsudomiT., et al. (2004). Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene, 23, 5360–5370.
50.
TomidaS., TakeuchiT., ShimadaY., ArimaC., MatsuoK., MitsudomiT., et al. (2009). Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol, 10, 2793–2799.
51.
TopalianS.L., HodiF.S., BrahmerJ.R., GettingerS., SmithD., McDermottD., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 366, 2443–2454.
52.
WooE.Y., ChuC.S., GoletzT.J., SchliengerK., YehH., CoukosG., et al. (2001). Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 61, 4766–4772.
53.
YuY., ZengD., OuQ., LiuS., LiA., ChenY., et al. (2019). Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Netw Open 2,e196879.
54.
ZhuC.Q., DingK., StrumpfD., WeirB.A., MeyersonM., PennellN., et al. (2010). Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol, 28, 4417–4424.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
